Tradestie Institutional Equity Comparison Engine

CONX vs AAPG โ€” Head-to-Head Terminal

6-dimension institutional benchmarking across valuation, multi-year operating margins, normalized momentum, and dealer gamma corridors.

Market Close: 2026-11-16 Buy Verdict Report Ask Alpha

Pillar 1 Executive Scorecard & Category Winner Tally

AAPG Overall Edge

AAPG Captures Institutional Edge (3โ€“0 Pillars ยท 9โ€“0 Matrix Metrics)

Tradestie Institutional Equity Comparison Engine assigns the overall head-to-head edge to Ascentage Pharma Group International American Depository Shares (AAPG) driven by superior Valuation, Growth & Margin, Momentum & Technical. Fundamentally, CONX trades at N/M Forward P/E with N/A operating margin (N/A YoY revenue) versus AAPG at 9.4x Forward P/E and -219.5% operating margin (+29.3% YoY). In options structure, CONX sits in UNCLASSIFIED (N/A IV; Dealer Gamma Walls on Pro) against AAPG sits in UNCLASSIFIED (N/A IV; Dealer Gamma Walls on Pro).

Valuation Winner AAPG
CONX N/M vs AAPG 9.4x Fwd P/E
Growth & Margin Winner AAPG
Op Margin N/A vs -219.5% ยท YoY N/A vs +29.3%
Momentum & Technical Winner AAPG
1Y -89.0% vs -60.2% ยท 52W Pos 0% vs 0%
Options & Structure Winner Tie
UNCLASSIFIED (N/A IV) vs UNCLASSIFIED (N/A IV)
CONX US Equity
CONX
Institutional Equity
$2.66
-11.75% 1D
Market Cap N/A
1M Return -54.66%
1Y Return -88.97%
Forward P/E N/M
Unified AI Score
42.0 / 100 HOLD
Tech 25.0 Fund 54.0 Flow 50.0 Mom 55.0
AAPG NASDAQ
Ascentage Pharma Group International American Depository Shares
Pharmaceutical Preparations
$13.29
-9.1% 1D
Market Cap $1.4B
1M Return -13.53%
1Y Return -60.21%
Forward P/E 9.4x
Unified AI Score
49.7 / 100 HOLD
Tech 58.0 Fund 57.0 Flow 50.0 Mom 60.0

Pillar 2 Normalized Relative Return Performance (% Indexed to 0%)

1Y Indexed Return: CONX -88.97% AAPG -60.21% Spread: +30.24 pp (AAPG Lead)

Pillar 3 Operating Profitability Benchmark (Trailing 12-Month)

Split-Invariant Revenue ($B) & Operating Margin (%)
CONX TTM Op. Margin: N/A AAPG TTM Op. Margin: -219.5%
Standardized multi-year USD domestic revenue schedules are unavailable for foreign-domiciled ADR filing schedules on CONX vs AAPG. Trailing 12-month operating profitability (CONX N/A vs AAPG -219.5%) and valuation multiples (CONX N/M vs AAPG 9.4x Forward P/E) are benchmarked directly in Pillar 4 below.

Pillar 4 Head-to-Head Fundamental & Valuation Matrix

Matrix Tally: CONX (0) vs AAPG (9)
Institutional Metric CONX AAPG Criterion Row Winner
Market Capitalization Scale N/A $1.4B Larger Scale AAPG
Trailing P/E Ratio Valuation N/M 9.4x Lower Multiple AAPG
Forward P/E Ratio Valuation N/M 9.4x Lower Multiple AAPG
Revenue Growth (YoY) Growth N/A +29.3% Higher Growth AAPG
Operating Margin (TTM) Profitability N/A -219.5% Higher Margin AAPG
Net Profit Margin Profitability N/A -228.5% Higher Margin AAPG
Return on Equity (ROE) Capital Efficiency N/A -236.6% Higher ROE AAPG
52-Week Range Position Momentum 0% ($3โ€“$28) 0% ($13โ€“$34) Stronger Trend Tie
Beta / 30D Volatility Risk Regime 4.88ฮฒ ยท 135% Vol 1.32ฮฒ ยท 70% Vol Lower Realized Risk AAPG
Unified Institutional Score Composite Signal 42.0 / 100 (HOLD) 49.7 / 100 (HOLD) Higher Composite AAPG

Pillar 5 Options Structure, IV Regime & Dealer Gamma Corridor

Full CONX vs AAPG Buy Guide
CONX UNCLASSIFIED
0d in phase ยท OBV NEUTRAL
Put Wall Floor Pro Only
Call Wall Magnet Pro Only
IV Percentile N/A
IV Regime Unclassified
Live CONX Put/Call Gamma Walls & dealer positioning signals require Pro. Unlock 14-Day Free Trial →
AAPG UNCLASSIFIED
0d in phase ยท OBV NEUTRAL
Put Wall Floor Pro Only
Call Wall Magnet Pro Only
IV Percentile N/A
IV Regime Unclassified
Live AAPG Put/Call Gamma Walls & dealer positioning signals require Pro. Unlock 14-Day Free Trial →

Pillar 6 90-Day Technical & R&D Innovation Disclosures

Corporate R&D & Foundry Tracker
Neither CONX nor AAPG registered frontier semiconductor/AI engineering publications in the trailing 90-day window; head-to-head edge is anchored on operating margin trajectory, valuation multiples, and options structure above.